Biblio
Export 623 results:
Author Title Type [ Year
Filters: Keyword is Alzheimer Disease [Clear All Filters]
“O-GlcNAcylation and Its Roles in Neurodegenerative Diseases.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1051-1068, 2024.
, “Olfactory Dysfunction and Alzheimer's Disease: A Review.”, J Alzheimers Dis, vol. 99, no. 3, pp. 811-827, 2024.
, “Optimizing the Implementation of a Lifestyle Dementia Prevention Intervention for Older Patients in an Academic Healthcare System.”, J Alzheimers Dis, vol. 100, no. 4, pp. 1237-1259, 2024.
, “Palliative Care in Nursing Home Residents with Young-Onset Dementia: Professional and Family Caregiver Perspectives.”, J Alzheimers Dis, vol. 97, no. 2, pp. 573-586, 2024.
, “Pharmacodynamic and Clinical Effects of Ginkgo Biloba Extract EGb 761 and Its Phytochemical Components in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. s1, pp. S285-S298, 2024.
, “Pharmacologic and Nutritional Interventions for Early Alzheimer's Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.”, J Alzheimers Dis, vol. 99, no. 4, pp. 1173-1186, 2024.
, “Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.”, J Alzheimers Dis, vol. 100, no. 2, pp. 563-578, 2024.
, “Psychosis in Neurodegenerative Dementias: A Systematic Comparative Review.”, J Alzheimers Dis, vol. 99, no. 1, pp. 85-99, 2024.
, “Quantitative Metabolomic Analysis of the Rat Hippocampus: Effects of Age and of the Development of Alzheimer's Disease-Like Pathology.”, J Alzheimers Dis, vol. 99, no. s2, pp. S327-S344, 2024.
, “Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42.”, J Alzheimers Dis, vol. 99, no. 3, pp. 877-881, 2024.
, “Recent Advances in Drug Delivery Systems Targeting Insulin Signalling for the Treatment of Alzheimer's Disease.”, J Alzheimers Dis, vol. 98, no. 4, pp. 1169-1179, 2024.
, “Regional differences in glucose metabolic decline and tau deposition in the Alzheimer's continuum brain.”, J Alzheimers Dis, vol. 102, no. 1, pp. 228-236, 2024.
, “Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 3, pp. 1261-1274, 2024.
, “The Role of Impaired Receptor Trafficking in Mediating the Pathological Effects of APOE4 in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 2, pp. 753-775, 2024.
, “A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories.”, J Alzheimers Dis, vol. 99, no. 3, pp. 843-856, 2024.
, “Senescence Targeting Methods Impact Alzheimer's Disease Features in 3xTg Mice.”, J Alzheimers Dis, vol. 97, no. 4, pp. 1751-1763, 2024.
, “Sex and Sleep Disruption as Contributing Factors in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 31-74, 2024.
, “Short-Term Practice Effects on Cognitive Tests Across the Late Life Cognitive Spectrum and How They Compare to Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. 1, pp. 321-332, 2024.
, “Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.”, J Alzheimers Dis, vol. 98, no. 2, pp. 643-657, 2024.
, “Sleep Biomarkers for Predicting Cognitive Decline and Alzheimer's Disease: A Systematic Review of Longitudinal Studies.”, J Alzheimers Dis, vol. 97, no. 1, pp. 121-143, 2024.
, “Small RNA Profiles of Brain Tissue-Derived Extracellular Vesicles in Alzheimer's Disease.”, J Alzheimers Dis, vol. 99, no. s2, pp. S235-S248, 2024.
, “Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.”, J Alzheimers Dis, vol. 97, no. 2, pp. 567-572, 2024.
, “A systematic review of lifestyle-based interventions for managing Alzheimer's disease: Insights from randomized controlled trials.”, J Alzheimers Dis, vol. 102, no. 4, pp. 943-966, 2024.
, “Targeting Caspases 3/6 and Cathepsins L/B May Decrease Laminopathy-Induced Apoptosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 101, no. 1, pp. 211-221, 2024.
, “Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.”, J Alzheimers Dis, vol. 101, no. s1, pp. S129-S140, 2024.
,